Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 655 and AMG 479 in Advanced Refractory Solid Tumors
NCT00819169Phase 2Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Jan 2009
- Primary completion
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of conatumumab in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PC), ovarian cancer, sponsored by ImmunityBio, Inc.. Started Jan 2009; status: terminated.
02
Drugs
conatumumab
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic cancer (PC)ovarian cancer
Beyond the preview
Go deeper on NCT00819169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00819169.